TOPICAL CYCLOSPORINE % 0.05 FOR THE TREATMENT OF SUBEPITHELIAL INFILTRATES SECONDARY TO ADENOVIRAL KERATOCONJUNCTIVITIS
S. Gur Gungor, Y. Aydin Akova, I. Kilic
Baskent University, Faculty of Medicine, Ankara, Turkey

Purpose: To evaluate the efficacy of topical cyclosporine A (CsA) % 0.05 in patients with subepithelial infiltrates (SEIs) secondary to adenoviral keratoconjunctivitis that are resistant to tapering of corticosteroid eye drops.
Method: Records of 18 eyes of 9 patients (7 women, 2 men) with SEIs who were treated with topical CsA % 0.05 were reviewed retrospectively. Age, follow-up duration, best corrected visual acuity (log-Mar) (BCVA) was recorded before and after treatment. Clinical response and side effects related to topical CsA were noted. Subjective and objective evaluations were done with a symptom questionnaire and image analysis programme (image j) by counting the number of SEIs, respectively.
Results: Nine patients with a mean age of 40.2±16.01 years were included. Mean follow up duration was 23 months (range 14-32). The mean BCVA before and after treatment was 0.17±0.2 and 0.12±0.29, respectively. All patients showed clinical improvement during the treatment period. There was statistically significant reduction in number of SEIs and severity of symptoms before and after the treatment. Full of patients noted improvement in vision, while most of them reported no foreign body sensation or glare. No side effects related to CsA was observed.
Conclusion: Topical CsA % 0.05 is an effective and well tolerated treatment option in patients with SEIs. Side effects make CsA safe superior to topical steroids.